The stock of Trinity Biotech plc (ADR) (NASDAQ:TRIB) is a huge mover today! About 331,018 shares traded hands. Trinity Biotech plc (ADR) (NASDAQ:TRIB) has declined 40.02% since March 3, 2016 and is downtrending. It has underperformed by 48.36% the S&P500.
The move comes after 8 months positive chart setup for the $149.55M company. It was reported on Oct, 6 by Barchart.com. We have $8.37 PT which if reached, will make NASDAQ:TRIB worth $46.36M more.
Analysts await Trinity Biotech plc (ADR) (NASDAQ:TRIB) to report earnings on October, 27. They expect $0.05 earnings per share, down 50.00% or $0.05 from last year’s $0.1 per share. TRIB’s profit will be $1.17 million for 31.95 P/E if the $0.05 EPS becomes a reality. After $0.06 actual earnings per share reported by Trinity Biotech plc (ADR) for the previous quarter, Wall Street now forecasts -16.67% negative EPS growth.
Trinity Biotech plc (ADR) (NASDAQ:TRIB) Ratings Coverage
Out of 4 analysts covering Trinity Biotech (NASDAQ:TRIB), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Trinity Biotech has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The company was initiated on Thursday, September 3 by Raymond James. The firm has “Buy” rating by TH Capital given on Wednesday, July 29. The rating was downgraded by Stephens on Wednesday, October 5 to “Equal-Weight”. As per Friday, October 23, the company rating was downgraded by Craig Hallum.
According to Zacks Investment Research, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.”
More notable recent Trinity Biotech plc (ADR) (NASDAQ:TRIB) news were published by: Barrons.com which released: “Trinity Biotech PLC ADR” on August 31, 2015, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on February 11, 2011, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on July 07, 2009. More interesting news about Trinity Biotech plc (ADR) (NASDAQ:TRIB) were released by: Benzinga.com and their article: “12 Biggest Mid-Day Losers For Tuesday” published on October 04, 2016 as well as Barrons.com‘s news article titled: “Trinity Biotech Is on the Road to Recovery” with publication date: October 31, 2015.
TRIB Company Profile
Trinity Biotech plc (Trinity Biotech), incorporated on January 22, 1992, develops, acquires, makes and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) divisions of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two divisions: the Americas and Rest of World. Trinity Biotech is a well-known provider of raw materials to the life sciences and research industries around the world. Trinity Biotech markets its portfolio of approximately 850 products to clients in approximately 100 countries around the world, through its sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech’s diagnostic products is the Americas, which consists of North America and South America. Trinity Biotech also sells raw materials to the life sciences industry and research institutes around the world, through its subsidiary, Benen Trading Ltd., trading as Fitzgerald Industries. Trinity Biotech sells its products through its direct sales organizations in the United States, Brazil and the United Kingdom, and through a network of principal distributors and non-governmental bodies into approximately 100 countries around the world. The Company’s products are classified as POC, emergency medicine, clinical laboratory and blood bank screening.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.